Retatrutide Side Effects: What the Trials Actually Show (2026)

What side effects did retatrutide trials report?

In the Phase 2 trial (Jastreboff et al., published in the New England Journal of Medicine in 2023, 338 adults with obesity over 48 weeks), the reported adverse events were, verbatim, that “the most common adverse events in the retatrutide groups were gastrointestinal; these events were dose-related, were mostly mild to moderate in severity, and were partially mitigated with a lower starting dose.” The gastrointestinal events were nausea, diarrhea, and vomiting.

The trial also noted dose-dependent increases in heart rate that peaked around 24 weeks. Two things to hold onto: the side-effect pattern is dose-related (higher doses, more GI effects), and these are trial figures on an investigational drug — not a settled real-world safety profile.

What are the most common side effects of retatrutide?
In its Phase 2 trial, the most common were gastrointestinal — nausea, diarrhea, and vomiting — which were dose-related, mostly mild to moderate, and reduced by a lower starting dose. The trial also noted dose-dependent heart-rate increases peaking around 24 weeks. All of this is trial data on an investigational drug, not a real-world safety profile.

Why are the side effects mostly gastrointestinal?

Retatrutide acts on GLP-1 among other hormone receptors, and GLP-1 receptor activation slows gastric emptying — the same mechanism behind the nausea, diarrhea, and vomiting seen with approved GLP-1 drugs like semaglutide and tirzepatide. The trials’ finding that a lower starting dose reduces these effects mirrors the “start low, go slow” titration used with the approved medications.

That mechanistic overlap is why retatrutide’s GI profile looks broadly familiar — but “familiar mechanism” is not the same as “known safety profile,” which only real-world approved use produces.

How much weight do people lose on retatrutide?

The trial figures, with their scope attached:

• Phase 2 (NEJM 2023, 48 weeks): least-squares mean weight change of −24.2% at the top 12 mg dose, versus −2.1% for placebo. Lower doses lost less (about −8.7% at 1 mg, −17.1% at 4 mg, −22.8% at 8 mg) — a clear dose-response.
• Phase 3 TRIUMPH-1 (Lilly, 2026, ~2,339 participants, 80 weeks): weight loss of up to 28.3% in the highest-dose arm, with all doses meeting the trial’s primary endpoint.

These are averages from controlled trials on selected participants — real-world results, if the drug is approved, will vary. And weight loss is only one side of the ledger; it comes with the dose-related GI effects above.

How much weight do people lose on retatrutide?
In the Phase 2 trial, an average of 24.2% at the 12 mg dose over 48 weeks (vs 2.1% for placebo), with a clear dose-response. Lilly’s Phase 3 TRIUMPH-1 trial reported up to 28.3% over 80 weeks. These are controlled-trial averages on an investigational drug; real-world results would vary if it’s approved.

Is retatrutide stronger than tirzepatide?

The honest answer is that no published head-to-head trial has compared retatrutide and tirzepatide, so a direct “stronger” claim isn’t supported by the kind of evidence that would settle it. What exists is separate trials: retatrutide’s Phase 3 reported up to ~28% average weight loss over 80 weeks, and tirzepatide’s trials report high figures too — but comparing across different trials, populations, and durations is not the same as a randomized head-to-head, and cross-trial numbers can mislead.

Retatrutide is also mechanistically different — it acts on three hormone receptors (including glucagon) rather than tirzepatide’s two — which is why it’s of interest, but mechanism doesn’t establish superiority. Until a head-to-head trial is published, “stronger” is an open question, not a fact.

Is retatrutide stronger than tirzepatide?
No published head-to-head trial has compared them, so a direct “stronger” claim isn’t supported. Retatrutide’s Phase 3 reported up to ~28% average weight loss and tirzepatide’s trials are also high, but comparing across separate trials and populations isn’t a randomized head-to-head. Retatrutide acts on three receptors vs tirzepatide’s two, but mechanism alone doesn’t prove superiority.

What is retatrutide, and how is it different from tirzepatide?

Retatrutide is a single molecule that activates three gut/metabolic hormone receptors — GIP, GLP-1, and glucagon — often called a “triple agonist.” Tirzepatide (Zepbound, Mounjaro) is a “dual agonist,” activating GIP and GLP-1. The added glucagon-receptor activity is the main structural difference and part of why retatrutide is being studied for potentially larger metabolic effects.

The practical difference today is simpler: tirzepatide is FDA-approved and available with a prescription; retatrutide is investigational and available only within clinical trials. For a decision you can actually act on now, that gap matters more than the receptor count.

How is retatrutide different from tirzepatide?
Retatrutide is a triple agonist acting on GIP, GLP-1, and glucagon receptors; tirzepatide is a dual agonist acting on GIP and GLP-1. The added glucagon activity is the key structural difference. Practically, tirzepatide is FDA-approved and prescribable now, while retatrutide is investigational and available only in clinical trials.

A necessary caution: this is an unapproved drug.

Everything above describes a medication that cannot be legally prescribed or sold for human use today. The FDA has stated retatrutide “cannot be used in compounding under federal law,” and it issued warning letters to sellers of “research” retatrutide products in September 2025. Any product you can buy online now is unapproved, unregulated, and of unknown identity and purity — the trial safety data on this page does not apply to it.

If and when retatrutide is approved, its side-effect profile will be defined by an FDA label and real-world use. Until then, the safe path is approved GLP-1 medications under a prescriber’s care.